Atrás
Precio CervoMed Inc (CRVO)
Gráfico del Precio de Acciones CRVO
CRVO Ganando
CervoMed Inc
$4.72
4.19%
$0.18
Al cierre: Feb 13, 16:00:00 GMT-5
$4.7
-0.42%
$-0.01
Mercado Posterior: Feb 13, 20:00:00 GMT-5
Estadísticas clave
Cierre Anterior
$4.53
Precio de apertura
$4.56
Rango del día
$4.56 - $4.84
Rango de 52 semanas
$1.92 - $16.94
Volumen
36.0K
Volumen promedio
75.2K
EPS (TTM)
-2.87
Rendimiento de dividendos
--
Cap. de mercado
$43.4M
¿Qué es CRVO?
CervoMed, Inc. is a clinical stage biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 15 full-time employees. The company went IPO on 2016-11-09. The firm is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. The company focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
Características
© 2026 Finture Development Limited. Todos los derechos reservados.